Home › Amyotrophic Lateral Sclerosis › Massachusetts › Boston
Amyotrophic Lateral Sclerosis clinical trials in Boston, MA
19 studies for Amyotrophic Lateral Sclerosis are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
RAPA-501 Therapy for ALS
RecruitingPhase 2/3
- Massachusetts General Hospital, Boston
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
RecruitingPhase 3
- Sean M. Healey & AMG Center for ALS, Boston
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
RecruitingPhase 2
- Dana Farber Cancer Institute, Boston
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RecruitingPhase 1/2
- Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
Recruiting
- Beth Israel Deaconess Medical Center, Boston
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
RecruitingPhase 2
- Zydus US010, Boston
ASSESS ALL ALS Study
RecruitingObservational studyHealthy volunteers welcome
- Massachusetts General Brigham, Boston
PREVENT ALL ALS Study
RecruitingObservational studyHealthy volunteers welcome
- Massachusetts General Brigham, Boston
Study of COYA 302 for the Treatment of ALS
RecruitingPhase 2/3
- Massachusetts General Hospital, Boston
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
RecruitingObservational studyHealthy volunteers welcome
- Massachusetts General Hospital, Boston
Tofersen in Non-SOD1 ALS
RecruitingPhase 2
- Massachusetts General Hospital, Boston
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Recruiting
- Massachusetts General Hospital, Boston
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Recruiting
- Massachusetts General Hospital, Boston
EIM Via the Myolex mScan as an ALS Biomarker
RecruitingObservational study
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
Recruiting
- Massachusetts General Hospital, Boston
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
RecruitingPhase 1
- Massachusetts General Hospital, Healey & AMG Center for ALS, Boston
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
RecruitingObservational study
- Mass General Hospital -MGH, Boston
Intermuscular Coherence as a Biomarker for ALS
RecruitingObservational studyHealthy volunteers welcome
- Massachusetts General Hospital, Boston
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
RecruitingObservational studyHealthy volunteers welcome
- Massachusetts General Hospital, Boston
About Amyotrophic Lateral Sclerosis
ALS stands for Amyotrophic Lateral Sclerosis, also called Lou Gehrig's disease. ALS affects the nervous system, causing muscle problems. Find out how.
More about Amyotrophic Lateral Sclerosis on MedlinePlus
Amyotrophic Lateral Sclerosis trials in other cities
- Philadelphia, PA14 studies
- Jacksonville, FL13 studies
- Baltimore, MD13 studies
- New York City, NY11 studies
- Chicago, IL10 studies
- San Diego, CA10 studies
- San Francisco, CA10 studies
- St. Louis, MO9 studies
- Phoenix, AZ8 studies
- Dallas, TX8 studies
- Atlanta, GA8 studies
- Washington, DC7 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.